Biocon [BIOCON] vs GlaxoSmithKline [GLAXO] Detailed Stock Comparison
Biocon
NSE
Loading...
GlaxoSmithKline
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Biocon wins in 7 metrics, GlaxoSmithKline wins in 13 metrics, with 0 ties. GlaxoSmithKline appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Biocon | GlaxoSmithKline | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 113.56 | 49.26 | GlaxoSmithKline |
| Price-to-Book Ratio | 2.01 | 24.05 | Biocon |
| Debt-to-Equity Ratio | 66.26 | 0.51 | GlaxoSmithKline |
| PEG Ratio | -1.19 | 3.96 | Biocon |
| EV/EBITDA | 19.66 | 37.87 | Biocon |
| Profit Margin (TTM) | 2.44% | 25.41% | GlaxoSmithKline |
| Operating Margin (TTM) | 7.46% | 29.27% | GlaxoSmithKline |
| EBITDA Margin (TTM) | 7.46% | 29.27% | GlaxoSmithKline |
| Return on Equity | 3.66% | 47.54% | GlaxoSmithKline |
| Return on Assets (TTM) | 1.72% | 22.58% | GlaxoSmithKline |
| Free Cash Flow (TTM) | $17.18B | $12.65B | Biocon |
| Dividend Yield | 0.26% | 1.65% | GlaxoSmithKline |
| 1-Year Return | -2.68% | -1.72% | GlaxoSmithKline |
| Price-to-Sales Ratio (TTM) | 3.08 | 12.55 | Biocon |
| Enterprise Value | $634.39B | $444.42B | Biocon |
| EV/Revenue Ratio | 4.02 | 11.88 | Biocon |
| Gross Profit Margin (TTM) | 64.06% | 64.27% | GlaxoSmithKline |
| Revenue per Share (TTM) | $131 | $221 | GlaxoSmithKline |
| Earnings per Share (Diluted) | $3.20 | $56.24 | GlaxoSmithKline |
| Beta (Stock Volatility) | 0.23 | 0.04 | GlaxoSmithKline |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Biocon vs GlaxoSmithKline Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Biocon | 0.12% | 4.41% | -2.32% | 10.01% | 11.96% | -1.38% |
| GlaxoSmithKline | 1.15% | -0.53% | -2.07% | -20.08% | 2.86% | 24.11% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Biocon | -2.68% | 20.37% | -16.02% | 399.59% | 530.99% | 847.88% |
| GlaxoSmithKline | -1.72% | 93.88% | 65.40% | -16.90% | 44.53% | 513.71% |
Performance & Financial Health Analysis: Biocon vs GlaxoSmithKline
| Metric | BIOCON | GLAXO |
|---|---|---|
| Market Information | ||
| Market Cap | ₹485.52B | ₹478.18B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 2,035,256 | 106,935 |
| 90 Day Avg. Volume | 3,068,471 | 122,228 |
| Last Close | ₹364.15 | ₹2,802.20 |
| 52 Week Range | ₹291.00 - ₹406.00 | ₹1,921.00 - ₹3,515.70 |
| % from 52W High | -10.31% | -20.29% |
| All-Time High | ₹487.75 (Dec 21, 2020) | ₹3,872.00 (Mar 28, 2016) |
| % from All-Time High | -25.34% | -27.63% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.15% | -0.01% |
| Quarterly Earnings Growth | -0.95% | 0.12% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | 0.25% |
| Operating Margin (TTM) | 0.07% | 0.29% |
| Return on Equity (TTM) | 0.04% | 0.48% |
| Debt to Equity (MRQ) | 66.26 | 0.51 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹180.66 | ₹115.19 |
| Cash per Share (MRQ) | ₹38.10 | ₹147.46 |
| Operating Cash Flow (TTM) | ₹17.78B | ₹12.73B |
| Levered Free Cash Flow (TTM) | ₹10.13B | ₹9.28B |
| Dividends | ||
| Last 12-Month Dividend Yield | 0.26% | 1.65% |
| Last 12-Month Dividend | ₹1.00 | ₹54.00 |
Valuation & Enterprise Metrics Analysis: Biocon vs GlaxoSmithKline
| Metric | BIOCON | GLAXO |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 113.56 | 49.26 |
| Forward P/E | 36.63 | 47.85 |
| PEG Ratio | -1.19 | 3.96 |
| Price to Sales (TTM) | 3.08 | 12.55 |
| Price to Book (MRQ) | 2.01 | 24.05 |
| Market Capitalization | ||
| Market Capitalization | ₹485.52B | ₹478.18B |
| Enterprise Value | ₹634.39B | ₹444.42B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 4.02 | 11.88 |
| Enterprise to EBITDA | 19.66 | 37.87 |
| Risk & Other Metrics | ||
| Beta | 0.23 | 0.04 |
| Book Value per Share (MRQ) | ₹180.66 | ₹115.19 |
Financial Statements Comparison: Biocon vs GlaxoSmithKline
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BIOCON | GLAXO |
|---|---|---|
| Revenue/Sales | ₹39.10B | ₹8.05B |
| Cost of Goods Sold | ₹14.05B | ₹2.88B |
| Gross Profit | ₹25.05B | ₹5.17B |
| Research & Development | ₹-346.00M | N/A |
| Operating Income (EBIT) | ₹2.94B | ₹2.36B |
| EBITDA | ₹8.29B | ₹2.95B |
| Pre-Tax Income | ₹969.00M | ₹2.79B |
| Income Tax | ₹77.00M | ₹739.70M |
| Net Income (Profit) | ₹892.00M | ₹2.05B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BIOCON | GLAXO |
|---|---|---|
| Cash & Equivalents | ₹32.27B | ₹5.39B |
| Total Current Assets | ₹162.86B | ₹34.10B |
| Total Current Liabilities | ₹143.34B | ₹19.05B |
| Long-Term Debt | ₹129.45B | ₹24.92M |
| Total Shareholders Equity | ₹277.13B | ₹19.51B |
| Retained Earnings | ₹189.59B | ₹10.59B |
| Property, Plant & Equipment | ₹4.32B | ₹2.70B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BIOCON | GLAXO |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | BIOCON | GLAXO |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 2,035,256 | 106,935 |
| Average Daily Volume (90 Day) | 3,068,471 | 122,228 |
| Shares Outstanding | 1.20B | 169.41M |
| Float Shares | 523.92M | 41.29M |
| % Held by Insiders | 0.56% | 0.76% |
| % Held by Institutions | 0.24% | 0.08% |
Dividend Analysis & Yield Comparison: Biocon vs GlaxoSmithKline
| Metric | BIOCON | GLAXO |
|---|---|---|
| Last 12-Month Dividend | ₹1.00 | ₹54.00 |
| Last 12-Month Dividend Yield | 0.26% | 1.65% |
| 3-Year Avg Annual Dividend | ₹1.33 | ₹59.33 |
| 3-Year Avg Dividend Yield | 0.36% | 1.86% |
| 3-Year Total Dividends | ₹4.00 | ₹178.00 |
| Ex-Dividend Date | Jul 04, 2025 | May 30, 2025 |